semaglutide effect on thyroid (Ozempic) carries FDA warnings for C-cell tumors based rodent studies, with emerging human data showing higher thyroid cancer risk in early users. Over 2,900 lawsuits allege inadequate warnings for Ozempic linked to thyroid cancer

The move should draw the attention of pharma marketers navigating obesity and metabolic drug promotion

This lessens the likelihood of eating past the point of fullness and/or comfort

Introduction: The rapid expansion of GLP-1 receptor agonist therapeutics has increased the need for robust GLP-1 Biosimilar Characterization strategies

your provider monitors thyroid function, kidney health, and gastrointestinal symptoms during extended use

Impact on Obesity-Related Gastrointestinal Complications GLP-1 agonists and dual agonists like tirzepatide can have both positive and negative effects on obesity-related gastrointestinal conditions